MEKi inhibits MAPK signaling in stromal and immune cells as well as tumor cells so we also assessed COX2 expression levels in 3LL ΔNRAS and KPARG12C tumors from mice treated with MRTX849, as KRASG12C inhibitors only target tumor cells. This evidence concerns the gene PTGS2 and neoplasm.